Clinical development of anti-RANKL therapy by Schwarz, Edward M & Ritchlin, Christopher T
Page 1 of 6
(page number not for citation purposes)
Available online http://arthritis-research.com/content/9/S1/S7
Abstract
The receptor activator of nuclear factor-κB ligand (RANKL), its
cognate receptor RANK, and its natural decoy receptor
osteoprotegerin have been identified as the final effector molecules
of osteoclastic bone resorption. This has provided an ideal target
for therapeutic interventions in metabolic bone disease. As
described in previous reviews in this supplement, RANKL signaling
is required for osteoclast differentiation, activation, and survival.
Furthermore,  in vivo inhibition of RANKL leads to immediate
osteoclast apoptosis, and there are no in vivo models of bone
resorption that are refractory to RANKL inhibition. Thus, the only
step remaining in the development of a clinical intervention is the
generation of a safe, effective, and specific drug that can inhibit
RANKL in humans. Here we review the clinical development of
denosumab (formerly known as AMG 162), which is a fully human
mAb directed against RANKL. This discussion includes the
breadth of 21 human studies that have led to the current phase 3
clinical trials seeking approval for use of this agent to treat
postmenopausal women with low bone mineral density
(osteoporosis) and patients with metastatic lytic bone lesions
(multiple myeloma, and prostate and breast cancer).
Introduction
As discussed in previous reviews in this supplement, a
specific inhibitor of receptor activator of nuclear factor-κB
ligand (RANKL) could be of great therapeutic value in the
treatment of patients with a variety of metabolic and inflam-
matory bone disorders. Numerous biologic agents have been
developed, including protein ligands (calcitonin [Miacalcin™;
Novartis, East Hanover, NJ, USA], parathyroid hormone
[Forteo™; Eli Lilly, Indianapolis IN, USA], and bone
morphogenetic protein-2 [Infuse™; Medtronic, Memphis, TN,
USA]), soluble receptors (tumor necrosis factor [TNF]
receptor-Fc [Enbrel™; Amgen, Thousand Oaks, CA, USA]
and cytotoxic T-lymphocyte associated antigen-4
immunoglobulin [Orencia™; Bristol-Myers Squibb, New York,
NY, USA]), and mAbs (anti-TNF [Remicade™; Centocor,
Horsham, PA, USA and Humira™; Abbott, Abbott Park, IL,
USA] and anti-CD20 [Rituxan™; Genentech, San Francisco,
CA, USA]). These have emerged as drugs of choice for many
conditions as they are effective and, because they target a
single molecular interaction, they are relatively safe. This
specificity is largely due to the hundreds of millions of years
of evolution (ligands and receptors) or more than 1012 DNA
recombination events (mAbs) that occur to produce a high-
affinity (>10-9 M) interaction with only one other protein in the
body. Methods to achieve this kind of specificity with small
molecule drugs are not available. Thus, even with rational
drug design approaches based on atomic structures,
undesirable interactions with other proteins that cause severe
side effects often occur. Furthermore, some of these side
effects only occur in humans, and so the first signals may only
appear in clinical trials or postmarketing reports.
Development of a specific biologic agent for the treatment of
human disease requires the evaluation of several different
iterations and formulations. Indeed, this was the case for
denosumab. Natural antagonists to RANKL were produced first
because it was relatively easy to clone the cDNAs for RANK
[1] and OPG [2] into expression vectors that would produce
large amounts of the encoded proteins (receptor activator of
nuclear factor-κB [RANK] and osteoprotegerin [OPG],
respectively) in vitro. To facilitate their use in animal models, the
Fc portion of the immunoglobulin heavy chain was fused to the
amino-terminus of OPG (Fc-OPG) and the carboxyl-terminus of
RANK (RANK-Fc) to generate effective recombinant proteins.
The Fc domain allows for the dimerization required for high
affinity to trimeric RANKL; it facilitates large-scale purification
via protein A or protein G column chromatography; and it
dramatically increases biodistribution and pharmacokinetics of
the recombinant proteins in vivo. RANK-Fc and OPG-Fc
proved to be very specific and effective inhibitors, and
essentially all published preclinical studies to date have used
these recombinant proteins [3].
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Clinical history of Fc-OPG
Amgen Inc. (Thousand Oaks, CA, USA) performed the first
clinical trial to evaluate the efficacy of RANKL inhibition using
recombinant Fc-OPG as a drug in postmenopausal women
with osteoporosis [4]. This phase 1 study was designed to
evaluate the effect of a single subcutaneous dose (placebo,
0.1, 0.3, 1.0, or 3.0 mg/kg) on bone resorption, and the primary
outcome measures were biochemical markers of collagen
catabolism (urinary N-telopeptide [NTX] and deoxypyridino-
line). The highest dose yielded an approximate 80%
decrease in NTX levels 4 days after dosing and significant
effects lasted for 45 days. The study also evaluated the
effects of Fc-OPG on osteoblasts by monitoring serum levels
of bone-specific alkaline phosphatase (BSAP), which were
largely unaffected by the drug. Because Fc-OPG was well
tolerated by all patients and no serious adverse events were
reported, the investigators concluded that this RANKL
inhibitor is a viable candidate.
A subsequent phase 1 trial evaluated a different formulation
of OPG known as AMGN-0007 in patients with multiple
myeloma or breast carcinoma who exhibited radiologically
confirmed lytic bone lesions [5]. Because ethical
considerations prohibit the use of placebo in such cancer
patients, a double dummy, active controlled study design was
used, in which each patient received either a single
subcutaneous injection of AMGN-0007 (0.1, 0.3, 1.0, or
3.0 mg/kg) accompanied by intravenous placebo, or
intravenous pamidronate (90 mg) accompanied by sub-
cutaneous placebo. Although the study found AMGN-0007
to be well tolerated and that its effects on bone resorption
were similar to those of pamidronate, this was to be the last
clinical trial with OPG. The reasons for this were described
by Bekker and coworkers [6] and stem largely from the facts
that AMG 162 (denosumab) is superior to Fc-OPG in that it
yields greater decreases in bone turnover markers at lower
doses and it has a longer duration of antiresorptive effect at
equivalent doses. Those authors also cited two potential
concerns with Fc-OPG therapy that do not apply to AMG
162. The first is the generation of anti-Fc-OPG antibodies,
which might cross-react with endogenous Fc-OPG,
neutralizing its activity. The second potential concern is
binding of Fc-OPG to TNF-related apoptosis-inducing ligand
[7], which could inhibit its role in tumor surveillance. Thus, it
has been proposed that AMG 162 is safer and more
efficacious than Fc-OPG as a therapeutic inhibitor of RANKL.
Denosumab: a fully human mAb directed
against RANKL
Denosumab is a fully human mAb directed against RANKL
and is currently under investigation in phase 3 clinical trials
[8,9]. Denosumab was generated by immunizing the
XenoMouse [10] with full-length human RANKL protein. This
immunization produced a fully human IgG1 mAb, known as
AMG 161, which recognized an epitope with a single amino
acid difference between the mouse and human sequences
(Kostenuik PJ, personal communication). Because human
IgG1 can direct complement-dependent cytotoxicity or
antibody-dependent cell cytotoxicity to target cells [11], there
was concern that AMG 161 would have an undesirable toxic
profile caused by death of RANKL-producing cells (stromal
cells, osteoblasts, and T cells). Thus, it was converted to a
noncytotoxic IgG2 mAb, known as AMG 162, which has an
extremely high affinity (Kd approximately 10-12 M) for human
RANKL. The fact that it does not recognize rodent RANKL
has complicated preclinical development somewhat, in that
the only relevant animal data were derived from studies
conducted in cynomolgus monkeys [12].
Clinical experience with denosumab
Table 1 summarizes the 21 clinical trials to date that investi-
gated the effects of denosumab in patients with post-
menopausal osteoporosis (PMO), prostate cancer, breast
cancer, multiple myeloma, solid tumors, and rheumatoid
arthritis (RA). The initial phase 1 studies in PMO [6], and
multiple myeloma or breast cancer [13] focused on pharmaco-
kinetics and pharmacodynamics while monitoring adverse
events. Both studies evaluated the effects of a single sub-
cutaneous injection (0.01, 0.03, 0.1, 0.3, 1.0, or 3.0 mg/kg)
and monitored denosumab levels in serum and urine NTX
levels. The results revealed that the drug effects had a rapid
onset (within 12 hours) and were sustained in some patients
for up to 6 months. In the trial conducted by Bekker and
coworkers (in osteoporosis) [6] the maximum half-life was
32 days. In beast cancer and multiple myeloma the mean half-
lives were 46.3 and 33.3 days, respectively [13]. No drug-
related serious adverse events occurred in these phase 1
studies.
A phase 2 trial conducted to identify an ideal dose and
treatment regimen for denosumab in PMO was recently
completed [14], with the primary end-point being bone
mineral density (BMD). Similar studies were conducted in
patients with metastatic cancer, but the primary outcome was
urine NTX [15,16]. Four other phase 2 trials are ongoing.
These include a head-to-head comparison of denosumab
with alendronate in PMO using bone structure as the primary
outcome measure; a trial evaluating the efficacy of
denosumab in treating multiple myeloma, in which complete
and partial responses will be assessed; and an evaluation of
the anti-RANKL effects of denosumab (60 or 180 mg sub-
cutaneously every 6 months) on cartilage degradation and
bone erosion (assessed using plain radiographs and
magnetic resonance imaging) in RA. The 6-month magnetic
resonance imaging data from the RA trial were presented in
November at the American College of Rheumatology annual
meeting [17]. The results indicate that, compared with placebo,
the 180 mg group exhibited significantly less progression of
bone erosions compared with placebo (P < 0.019). Although
progression in the 60 mg group was also numerically less
than that with placebo, this did not reach significance
(P = 0.247). These results are consistent with the finding thatPage 3 of 6
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Table 1
Clinical trials investigating the effects of denosumab
Study name or title on www.clinicaltrials.gov Phase n Primary end-point
Osteoporosis
A single dose, placebo-controlled study of AMG 162, a fully human mAb to RANKL, in  phase 1 49 Pharmacokinetics 
postmenopausal women [6] and 
pharmacodynamics
A randomized, double-blind, placebo-controlled, multidose phase 2 study to determine the  phase 2 412 BMD
efficacy, safety, and tolerability of AMG 162 in the treatment of postmenopausal women 
with low BMD [14]
A randomized, double-blind, placebo-controlled, dose-response study of AMG 162  phase 2 – BMD
(denosumab) in Japanese postmenopausal osteoporotic women
A multicenter, randomized, placebo-controlled, pilot microCT study to estimate the effect of  phase 2 240 Distal radius 
treatment with denosumab (AMG 162) and alendronate sodium in postmenopausal women  measurements as 
with low BMD determined by 
Xtreme CT
A study to evaluate AMG 162 in the treatment of postmenopausal osteoporosis  phase 3 7,800 Fracture
A randomized, double-blind study to compare the efficacy of treatment with denosumab  phase 3 1,100 BMD
with that of alendronate sodium in postmenopausal women with low BMD
A randomized, double-blind study to evaluate safety and efficacy of transitioning therapy  phase 3 500 BMD
from alendronate to denosumab (AMG 162) in postmenopausal women with low BMD
A randomized, double-blind study to evaluate AMG 162 in the prevention of  phase 3 300 BMD
postmenopausal osteoporosis
An open-label, single arm extension study to evaluate the long-term safety of denosumab  Phase 3 – Safety
administration in postmenopausal women with low BMD
Bone metastases/multiple myeloma
A study of the biological RANKL inhibitor denosumab in subjects with multiple myeloma or  phase 1 54 Pharmacokinetics 
bone metastases from breast cancer [13] and 
pharmacodynamics
Randomized, active-controlled study of denosumab (AMG162) in breast cancer patients  phase 2 255 Urine NTX
with bone metastasis previously treated with intravenous bisphosphonates [16]
A randomized trial of denosumab (AMG 162) versus intravenous bisphosphonates in  phase 2 135 Urine NTX
cancer patients with bone metastases on established IV BP and evidence of elevated 
bone resorption [15]
An open-label, multicenter, phase 2 trial of denosumab in the treatment of relapsed or  phase 2 100 Complete 
plateau-phase multiple myeloma response/
partial response
An open-label, multicenter, phase 2 safety and efficacy study of denosumab (AMG 162)  phase 2 25 Response rate based 
in subjects with recurrent or unresectable giant cell tumor (GCT) of bone on imaging or tissue 
samples
A randomized, double-blind multicenter study of denosumab compared with zoledronic  phase 3 1,700 Skeletal related 
acid in the treatment of bone metastases in men with hormone-refractory prostate  events
cancer
A randomized, double-blind, multicenter study of denosumab compared with zoledronic  phase 3 1,400 Skeletal related 
acid in the treatment of bone metastases in subjects with advanced breast cancer events
Double-blind study of denosumab compared with zoledronic acid in the treatment of bone  phase 3 1,700 Skeletal related 
metastases in subjects with advanced cancer (excluding breast and prostate cancer) or  events
multiple myeloma
A randomized, double-blind, placebo-controlled, multicenter phase 3 study of  phase 3 1,400 Time to first 
denosumab on prolonging bone metastasis-free survival in men with hormone  occurence of bone
refractory prostate cancer metastasis or death
from any cause
Treatment-induced bone loss
A randomized, double-blind, placebo-controlled study to evaluate AMG 162 in the  phase 3 1,400 BMD
treatment of bone loss in patients undergoing androgen deprivation therapy for 
nonmetastatic prostate cancer
A randomized, double-blind, placebo-controlled study to evaluate AMG 162 in the  phase 3 208 BMD
treatment of bone loss in patients undergoing aromatase inhibitor therapy for 
nonmetastatic breast cancer
Rheumatoid arthritis
A randomized, double-blind, placebo-controlled, multidose phase 2 study to determine  phase 2 227 Bone erosions
the efficacy, safety, and tolerability of AMG 162 in the treatment of rheumatoid arthritis [17]
CT, computed tomography; mAb, monoclonal antibody; NTX, N-telopeptide; RANKL, receptor activator of nuclear factor-κB ligand.markers of bone resorption (serum collagen C-terminal
crosslinked peptide [CTX]-I and procollagen type 1 intact
N-terminal propeptide [P1NP]) and cartilage loss (urine
CTX-II) were significantly decreased [18], and BMDs in the
lumbar spine, total hip, and trochanter were significantly
increased [19] in these RA patients on denosumab therapy.
Currently, there are 10 ongoing phase 3 clinical trials with
denosumab for either PMO (60 mg subcutaneously every
6 months) or cancer (120 subcutaneously monthly). The
largest is an international study in PMO in which drug effects
on fracture reduction will be assessed. The other PMO trials
will examine effects on BMD either as a head-to-head
comparison with alendronate, after transition from bisphos-
phonate therapy, or as a prophylaxis in postmenopausal
women. Additional pre-metastatic prostate cancer and breast
cancer trials are underway that will analyze the effect of
denosumab on bone loss related to androgen deprivation
therapy and aromatase inhibitor therapy, respectively
(Table 1). Another central question in the area of tumor
metastasis is whether inhibition of bone remodeling will
influence disease progression in terms of prolonging bone
metastasis free survival in men with hormone refractory
prostate cancer who have no bone metastases at baseline, or
in terms of reducing skeletal related events (including
pathologic fracture, radiation therapy to bone, surgery to
bone, and spinal cord compression) in patients with bone
metastases from prostate cancer, breast cancer, and solid
tumors (Table 1).
Potential side effects of denosumab therapy
Three potential side effects have been identified based on
information derived from the biology of RANKL, the literature
on preclinical models of RANKL inhibition, and clinical
experience of bisphosphonate therapy to date. Considerable
effort has been invested in looking for signals related to these
adverse events in the denosumab trials [20].
Frozen bone
The first potential side effect is so-called ‘frozen bone’, a
process whereby complete inhibition of remodeling leads to
accumulation of microfractures and brittle bone. In fact,
concerns were raised regarding this complication in
postmenopausal women receiving bisphosphonate therapy,
based on findings from animal studies [21]. However, the
fragility fractures that were predicted to occur in this
population of patients, who have been treated with
alendronate for more than 10 years, have not materialized.
Frozen bone is less of an issue with denosumab in part
because it is completely cleared from the body; this is in
contrast to the more potent bisphosphonates, for which the
half-life in bone may be 5 years or longer. The issue of
decreased fracture healing has also been addressed in animal
experiments [22]. These studies demonstrated that RANK-
knockout mice are able to heal their fractures, and therefore
osteoclasts are not required to generate a union. The studies
also indicated that discontinuing RANKL inhibition at the time
of fracture in wild-type mice results in normal healing.
Immunosuppression
RANK-RANKL signaling was originally identified as a co-
stimulatory pathway during T-cell activation [23], and RANK
[24] and RANKL [25] knockout mice have altered
lymphocyte development and lack lymph nodes. These facts
have led to a concern regarding potential immunosuppres-
sion. Subsequent findings, however, have revealed that the
role of RANK-RANKL co-stimulation in T-cell activation is
only evident in the absence of CD40-CD40 ligand signaling
[26]. It has also been shown that RANKL inhibition with
OPG does not alter cellular or humoral immunity, or render
mice susceptible to bacterial challenge [27]. Thus, although
dendritic cells and T lymphocytes express these molecules,
it would appear that they play a minor or redundant role in
the mammalian immune response. Of course, close attention
will be given to the incidence of infection and neoplasms in
the larger phase 3 trials.
Osteonecrosis of the jaw
Osteonecrosis of the jaw (ONJ) has recently emerged as an
adverse side effect of bisphosphonate therapy [28,29].
Currently, the nature of ONJ remains enigmatic, and its cause
is a topic of great debate. Although it has been established
that 94% of published cases occurred in cancer patients who
received intravenous nitrogen-containing bisphosphonates,
ONJ has also been reported in healthy women who take oral
bisphosphonates for PMO. It is also known that 60% of
cases are preceded by a dental surgical procedure, and so it
has been proposed that the etiology of ONJ involves
oversuppression of bone turnover combined with infection
and possibly additional, as yet unidentified co-morbidities.
Based on the serious nature of ONJ and our lack of
knowledge on its etiology, the American Society for Bone and
Mineral Research has commissioned a task force to
investigate this problem [30]. Thus, until we have additional
data, investigators should be aware of this potentially severe
complication, and practice vigilant monitoring of patients who
take all forms of anticatabolic therapy for bone loss.
Advantages of denosumab over
bisphosphonates
Although the comparative ratios of risk to benefit for bis-
phosphonates and denosumab are currently unknown, there
are three potential advantages of denosumab over
bisphosphonates. As mentioned above, the first is that
denosumab is completely cleared over a relatively short
period of time, so that the effects on bone may not be long-
lasting. The second is that it could be the first anti-bone
resorbing agent to halt focal erosions and osteolysis. Over
the past two decades clinical trials designed to demonstrate
the effectiveness of bisphosphonates on erosions in RA have
repeatedly failed to show such an effect [31-33].
Interestingly, one of the more recent, well designed studies
Arthritis Research & Therapy    Vol 9 Suppl 1 Schwarz and Ritchlin
Page 4 of 6
(page number not for citation purposes)was able to demonstrate that etidronate therapy had a
favorable effect on general bone metabolism (osteopenia),
but it did not inhibit serum NTX levels or worsening of erosion
scores in patients with RA [34]. The results from these trials
are consistent with our preclinical studies, which showed that
TNF protects osteoclasts from alendronate-induced apop-
tosis by stimulating Bcl-xL expression through Ets-2 [35],
while RANKL inhibition in the same setting of inflammation
leads to rapid osteoclast apoptosis [36,37]. Thus, there is
great expectation that denosumab will effectively prevent
erosions in inflammatory arthritis and periprosthetic osteolysis.
Another disappointment of bisphosphonate therapy is the
inability to use these agents effectively and safely in
combination with anabolic agents. This was formally
demonstrated in the teriparitide and alendronate trial
conducted in patients with PMO [38]. Mechanistically, there
are two prevailing explanations for this. The first relates to
uncoupling of osteoclast-mediated bone resorption and new
bone formation by osteoblasts. If failure of combination
regimens results from uncoupling, then similar results to
those with alendronate are expected with denosumab. On the
other hand, if the lack of osteogenesis is due to osteoblast
toxicity, such as that observed in preclinical models [39],
which does not occur with RANKL inhibition [36,40], then
denosumab would be expected to work in combination with
anabolic agents.
Conclusion
The discovery of the RANK, RANKL, and OPG pathway as
the final effector of bone resorption has generated great
expectations regarding the potential of a biologic antagonist
for the treatment of patients with various metabolic and
inflammatory bone disorders. The broad clinical trial
experience to date indicates that denosumab may be a
biologic agent that can effectively inhibit bone resorption with
minimal side effects. The hope is that ongoing phase 3
clinical trials will demonstrate similar efficacy and safety
profiles for denosumab therapy in PMO and metastatic
cancer. Finally, looking to the future, it is not unreasonable to
expect that other metabolic bone diseases, which have been
refractory to bisphosphonates, will respond to this novel
therapeutic approach.
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